米希科：2025年走近东方：日本与韩国如何引领下一阶段临床开发新时代白皮书（英文版）

Once overlooked, Japan and South Korea have become valuable components of pharma’s commercial and clinical strategies. Japan is the third-largest market for pharmaceutical spending and the secondlargest Asia-Pacific market. Despite this activity, the country’s growing, aging population faces serious unmet need.1 According to recent data from Japan’s Pharmaceutical and Medical Devices Agency (PMDA), as of March 2023, 86 medicines that had been approved in Europe and/or the U.S. remained unavai